Over the past 50 years, Bayer Healthcare, Diagnostics has been revolutionizing the commercialization of biotechnology products and diagnostic systems. One of the largest diagnostic businesses in the world, Bayer Diagnostics has compiled an extensive history of technological firsts, including setting new diagnostic standards in diabetes and introducing the world's first automated instrument for clinical chemistry. The organization supports customers in 100 countries through an extensive portfolio of central, self-testing, nucleic acid and near patient care diagnostics systems and services for use in the assessment and management of health, including the areas of cardiovascular and kidney disease, oncology, virology, women's health and diabetes.

Bayer Healthcare, Diagnostics' global headquarters in the United States operates as part of Bayer HealthCare LLC, a member of the worldwide Bayer HealthCare group. With an annual R&D investment of over two hundred million dollars from its parent company, and approximately 7,000 employees, Bayer Diagnostics is equipped to become the leader in diagnostic technology.

Nucleic Acid Diagnostics Business Segment

Bayer Nucleic Acid Diagnostics (NAD) offers an innovative line of molecular assays and instrumentation. Dedicated to the constant incorporation of new ideas and development of disease-specific tests, Bayer's NAD assays utilize technologies of bDNA, TMA™, and PCR, to name a few. Strengthened by the acquisition of Chiron Diagnostics in 1998, Bayer Diagnostics continues to expand its innovate edge with a portfolio that now includes molecular diagnostic technology capable of benefiting the millions of patients with hepatitis and human immunodeficiency virus (HIV).